Guidance

Bionovo receives EMA final guidance for advancing Menerba to Phase 3 clinical trials

Bionovo, Inc. announced today that it has received final guidance from the European Medicines Agency (EMA) in order to advance Menerba, the company's lead drug candidate for menopausal symptoms, to Phase 3 clinical trials in Europe. The guidance defines the clinical and regulatory pathway to a European marketing authorization for Menerba.

Guidance Software to Demonstrate Forensic Approach to Security at Black Hat

LAS VEGAS----At the Black Hat 2010 USA Conference, Guidance Software, Inc. will demonstrate cyberforensic solutions that can help businesses, government agencies and other organizations expose, respond to and remediate security incidents.

Kellogg Cuts Full-Year Guidance

Kellogg has lowered its full-year earnings per share growth guidance to the range of 8% to 10% after reporting lower-than-expected earnings.